Aktuellt
SENASTE
Orexo's DTx segment is still encountering challenges and Zubsolv sales continue to decline. Marketing through social media might speed up sales of DTx ahead, but we still believe it has a long way to go before the segment contributes to significant revenues. We lower our valuation range to SEK 55-71 (66-85). Marketing material commissioned by Orexo.
LÄS MER
